Published in Arch Ophthalmol on January 10, 2011
TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema | NCT01870440
Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis (AZALEA) | NCT03097315
Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond) (2011) 1.10
Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal (2014) 1.05
Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis. Clin Ophthalmol (2013) 1.02
Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology (2013) 1.02
Intractable glaucoma necessitating dexamethasone implant (Ozurdex) removal and glaucoma surgery in a child with uveitis. BMJ Case Rep (2013) 1.00
Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol (2011) 1.00
Sustained-release corticosteroid options. J Ophthalmol (2014) 0.99
Role of the retinal vascular endothelial cell in ocular disease. Prog Retin Eye Res (2012) 0.99
Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmol (2013) 0.97
Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol (2015) 0.96
The future of uveitis treatment. Ophthalmology (2013) 0.92
Adult coats' disease successfully managed with the dexamethasone intravitreal implant (ozurdex®) combined with retinal photocoagulation. Case Rep Ophthalmol (2012) 0.89
Cystoid Macular Edema after Complicated Cataract Surgery Resolved by an Intravitreal Dexamethasone 0.7-mg Implant. Case Rep Ophthalmol (2011) 0.89
Ozurdex (a slow-release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial. Trials (2013) 0.88
Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes. J Ocul Pharmacol Ther (2014) 0.87
Novel dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitis. AAPS PharmSciTech (2014) 0.87
Steroid implant in anterior chamber of an aphakic vitrectomized eye. Graefes Arch Clin Exp Ophthalmol (2011) 0.86
Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye (Lond) (2012) 0.84
Surgical management in patient with uveitis. Indian J Ophthalmol (2013) 0.84
Evaluation of pain during intravitreal Ozurdex injections vs. intravitreal bevacizumab injections. Eye (Lond) (2014) 0.84
Update on corticosteroids for diabetic macular edema. Clin Ophthalmol (2016) 0.83
Liposomes and nanotechnology in drug development: focus on ocular targets. Int J Nanomedicine (2013) 0.83
Intravitreal devices for the treatment of vitreous inflammation. Mediators Inflamm (2012) 0.83
Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide. Exp Eye Res (2014) 0.83
Interobserver agreement in clinical grading of vitreous haze using alternative grading scales. Ophthalmology (2014) 0.82
Spontaneous relocation of a trapped retrolenticular slow-release dexamethasone implant (Ozurdex) in a silicone oil-filled eye of a pseudophakic patient. Eye (Lond) (2014) 0.82
Efficacy and tolerability of bilateral sustained-release dexamethasone intravitreal implants for the treatment of noninfectious posterior uveitis and macular edema secondary to retinal vein occlusion. Clin Ophthalmol (2015) 0.82
Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol (2014) 0.81
The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy. Dtsch Arztebl Int (2012) 0.81
Primed Mycobacterial Uveitis (PMU): Histologic and Cytokine Characterization of a Model of Uveitis in Rats. Invest Ophthalmol Vis Sci (2015) 0.81
Intravitreal Corticosteroids in the Management of Diabetic Macular Edema. Curr Ophthalmol Rep (2013) 0.81
Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis. Orphanet J Rare Dis (2015) 0.81
Pars Planitis: Epidemiology, Clinical Characteristics, Management and Visual Prognosis. J Ophthalmic Vis Res (2016) 0.81
[Intravitreal implants: drug carriers and carriers of hope?]. Ophthalmologe (2011) 0.80
Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema. Saudi J Ophthalmol (2014) 0.80
Effect of dexamethasone intravitreal implant in a corneal graft rejection. Int J Ophthalmol (2016) 0.79
Development of a preference-based index from the National Eye Institute Visual Function Questionnaire-25. JAMA Ophthalmol (2014) 0.79
Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis. Graefes Arch Clin Exp Ophthalmol (2015) 0.79
Single compartment drug delivery. J Control Release (2014) 0.79
Subconjunctival dexamethasone implant for non-necrotizing scleritis. J Ophthalmic Inflamm Infect (2013) 0.79
Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis. Eye (Lond) (2015) 0.79
An introduction to patient-reported outcome measures in ophthalmic research. Eye (Lond) (2014) 0.79
Drug delivery implants in the treatment of vitreous inflammation. Mediators Inflamm (2013) 0.78
Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report. J Med Case Rep (2016) 0.78
Efficacy and Safety in Retinal Vein Occlusion Treated with at Least Three Consecutive Intravitreal Dexamethasone Implants. J Ophthalmol (2016) 0.78
Ozurdex for the Treatment of a Patient with Birdshot Chorioretinopathy. Case Rep Ophthalmol (2015) 0.78
Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment. Orphanet J Rare Dis (2016) 0.78
New Immunosuppressive Therapies in Uveitis Treatment. Int J Mol Sci (2015) 0.77
Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res (2016) 0.77
Suprachoroidal Corticosteroid Administration: A Novel Route for Local Treatment of Noninfectious Uveitis. Transl Vis Sci Technol (2016) 0.77
Uveitis and gender: the course of uveitis in pregnancy. J Ophthalmol (2014) 0.77
Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye. Med Hypothesis Discov Innov Ophthalmol (2013) 0.77
Corticosteroid implants for chronic non-infectious uveitis. Cochrane Database Syst Rev (2016) 0.77
Evaluation of a prednisolone acetate-loaded subconjunctival implant for the treatment of recurrent uveitis in a rabbit model. PLoS One (2014) 0.77
Treatment of refractory uveitic macular edema with dexamethasone intravitreal implants in a pediatric patient with bilateral granulomatous idiopathic panuveitis: a case report. J Ophthalmic Inflamm Infect (2013) 0.77
A report of high intraocular pressure with the dexamethasone intravitreal implant. Arch Ophthalmol (2011) 0.76
Impact on intraocular pressure after 20-mg decanted triamcinolone acetonide (kenalog) injection when using prophylactic antiglaucoma therapy. Retina (2015) 0.76
Splitting of a Dexamethasone Implant (Ozurdex) following the Injection. Case Rep Ophthalmol Med (2013) 0.76
Results of intravitreal dexamethasone implant 0.7 mg (Ozurdex®) in non-infectious posterior uveitis. Int J Ophthalmol (2015) 0.76
[Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis: Date: 02/07/2014]. Ophthalmologe (2014) 0.76
Clinical trials in noninfectious uveitis. Int Ophthalmol Clin (2015) 0.75
Noninfectious uveitis: strategies to optimize treatment compliance and adherence. Clin Ophthalmol (2015) 0.75
A 10-year review of pediatric uveitis at a Hispanic-dominated tertiary pediatric ophthalmic clinic. Clin Ophthalmol (2016) 0.75
Advances in drug delivery to the posterior segment. Curr Opin Ophthalmol (2015) 0.75
Assessment of vitreous haze using ultra-wide field retinal imaging. J Ophthalmic Inflamm Infect (2016) 0.75
Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex® in patients with uveitic cystoid macular edema. Indian J Ophthalmol (2015) 0.75
Development of an activity disease score in patients with uveitis (UVEDAI). Rheumatol Int (2016) 0.75
Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes. J Ophthalmol (2016) 0.75
Phacoemulsification and intraocular lens implantation after inadvertent intracapsular injection of intravitreal dexamethasone implant. BMJ Case Rep (2012) 0.75
Uveitic Macular Edema: Treatment Update. Curr Ophthalmol Rep (2016) 0.75
Intravitreal dexamethasone implants for the treatment of refractory scleritis combined with uveitis in adult-onset Still's disease: a case report. BMC Ophthalmol (2016) 0.75
Management of noninfectious posterior uveitis with intravitreal drug therapy. Clin Ophthalmol (2016) 0.75
Comparison of In Vivo Gene Expression Profiling of RPE/Choroid following Intravitreal Injection of Dexamethasone and Triamcinolone Acetonide. J Ophthalmol (2016) 0.75
A national survey of Canadian ophthalmologists to determine awareness of published guidelines for the management of uveitis. J Ophthalmic Inflamm Infect (2016) 0.75
Efficacy of Ozurdex implant in treatment of noninfectious intermediate uveitis. Indian J Ophthalmol (2015) 0.75
Uveitic macular edema. Eye (Lond) (2016) 0.75
Morphological assessment of the retina in uveitis. J Ophthalmic Inflamm Infect (2016) 0.75
Birdshot uveitis: current and emerging treatment options. Clin Ophthalmol (2013) 0.75
Recent advances in managing and understanding uveitis. F1000Res (2017) 0.75
Sustained-release dexamethasone intravitreal implant in juvenile idiopathic arthritis-related uveitis. Int Ophthalmol (2016) 0.75
[Intermediate uveitis: guidelines of the German Ophthalmological Society and the Professional Association of German Ophthalmologists]. Ophthalmologe (2014) 0.75
[Therapy of intermediate uveitis]. Ophthalmologe (2014) 0.75
Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension. Graefes Arch Clin Exp Ophthalmol (2016) 0.75
The clinical outcomes of surgical management of anterior chamber migration of a dexamethasone implant (Ozurdex®). Graefes Arch Clin Exp Ophthalmol (2017) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology (2010) 7.30
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med (2010) 4.95
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology (2011) 4.61
A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol (2006) 4.55
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol (2003) 4.52
Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina (2011) 3.04
Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem (2005) 3.03
A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev (2006) 2.78
Factors determining visual outcome in endogenous Candida endophthalmitis. Retina (2012) 2.67
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol (2007) 2.53
Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 2.53
Toxoplasma gondii in the peripheral blood of patients with acute and chronic toxoplasmosis. Br J Ophthalmol (2010) 2.50
Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. Am J Hum Genet (2007) 2.40
Survival analysis of conjunctival limbal grafts and amniotic membrane transplantation in eyes with total limbal stem cell deficiency. Am J Ophthalmol (2005) 2.38
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23
A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum (2005) 2.20
Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci (2002) 2.19
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 2.19
Plasmapheresis for lupus retinal vasculitis. Arch Ophthalmol (2006) 2.13
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol (2006) 2.10
Efficient mitochondrial biogenesis drives incomplete penetrance in Leber's hereditary optic neuropathy. Brain (2013) 2.08
Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol (2005) 2.01
Genetic divergence of Toxoplasma gondii strains associated with ocular toxoplasmosis, Brazil. Emerg Infect Dis (2006) 2.00
Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. J Cell Biol (2009) 1.99
Haplogroup effects and recombination of mitochondrial DNA: novel clues from the analysis of Leber hereditary optic neuropathy pedigrees. Am J Hum Genet (2006) 1.95
INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY. Retina (2016) 1.92
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol (2008) 1.87
Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology (2011) 1.85
Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proc Natl Acad Sci U S A (2009) 1.84
Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol (2010) 1.82
Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J Exp Med (2002) 1.81
p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal (2011) 1.80
Recently acquired Toxoplasma gondii infection, Brazil. Emerg Infect Dis (2006) 1.79
In vivo identification of regulators of cell invasion across basement membranes. Sci Signal (2010) 1.77
Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75
Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol (2010) 1.75
One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol (2002) 1.70
Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology (2005) 1.69
Relapsing polychondritis: a clinical review. Semin Arthritis Rheum (2002) 1.68
Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology (2007) 1.66
Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol (2009) 1.64
Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm (2010) 1.62
Adverse effects of smoking on patients with ocular inflammation. Br J Ophthalmol (2010) 1.61
Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc Natl Acad Sci U S A (2012) 1.59
Methotrexate for ocular inflammatory diseases. Ophthalmology (2009) 1.58
Infectious post-LASIK crystalline keratopathy caused by nontuberculous mycobacteria. Cornea (2002) 1.57
Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial. Trials (2014) 1.56
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Ocular pemphigus. J Am Acad Dermatol (2005) 1.56
Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. Retina (2010) 1.56
Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology (2013) 1.52
Iris recognition as a biometric method after cataract surgery. Biomed Eng Online (2004) 1.51
The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol (2002) 1.48
A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology (2003) 1.48
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol (2005) 1.47
LAP-BAND for lower BMI: 2-year results from the multicenter pivotal study. Obesity (Silver Spring) (2013) 1.46
Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci (2011) 1.46
HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology (2009) 1.45
Azathioprine for ocular inflammatory diseases. Am J Ophthalmol (2009) 1.44
Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol (2009) 1.41
The genotype of Toxoplasma gondii strains causing ocular toxoplasmosis in humans in Brazil. Am J Ophthalmol (2005) 1.41
Secreted versus membrane-anchored collagenases: relative roles in fibroblast-dependent collagenolysis and invasion. J Biol Chem (2009) 1.37
Punctate inner choroidopathy: a survey analysis of 77 persons. Ophthalmology (2007) 1.36
Extracellular polymeric substances (EPS) of microbial aggregates in biological wastewater treatment systems: a review. Biotechnol Adv (2010) 1.35
Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res (2011) 1.35
Etiology and management of idiopathic orbital inflammation. Am J Ophthalmol (2004) 1.33
Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology (2005) 1.33
Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology (2012) 1.32
New developments in corticosteroid therapy for uveitis. Ophthalmologica (2010) 1.31
A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. J Exp Clin Cancer Res (2011) 1.27
Extensive investigation of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy. Am J Ophthalmol (2003) 1.27
An outbreak of Mycobacterium chelonae infection after LASIK. Ophthalmology (2003) 1.26
Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin (2006) 1.25
Evidence for a novel x-linked modifier locus for leber hereditary optic neuropathy. Ophthalmic Genet (2008) 1.24
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol (2008) 1.23
Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. Proc Natl Acad Sci U S A (2012) 1.23
Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology (2005) 1.22
Visual performance of AcrySof ReSTOR apodized diffractive IOL: a prospective comparative trial. Am J Ophthalmol (2006) 1.20
Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res (2004) 1.20
Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology (2002) 1.20
Biodegradable implants for sustained drug release in the eye. Pharm Res (2010) 1.20
Toxoplasmosis: a global threat. J Glob Infect Dis (2011) 1.19
Primary intraocular lymphoma: A review. Semin Ophthalmol (2006) 1.19
Acute posterior multifocal placoid pigment epitheliopathy: outcome and visual prognosis. Retina (2009) 1.19